Quarterly Snapshot: Quick and Current Ratios for Allogene Therapeutics Inc (ALLO)

The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The closing price of Allogene Therapeutics Inc (NASDAQ: ALLO) was $2.55 for the day, up 4.51% from the previous closing price of $2.44. In other words, the price has increased by $4.51 from its previous closing price. On the day, 10.1 million shares were traded. ALLO stock price reached its highest trading level at $2.57 during the session, while it also had its lowest trading level at $2.36.


Our analysis of ALLO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 12.80 and its Current Ratio is at 12.80. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.19.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on May 31, 2024, initiated with a Overweight rating and assigned the stock a target price of $11.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 18 ’24 when MESSEMER DEBORAH M. sold 18,641 shares for $2.28 per share. The transaction valued at 42,488 led to the insider holds 166,765 shares of the business.

Humer Franz B sold 11,200 shares of ALLO for $26,181 on May 30 ’24. The Director now owns 255,253 shares after completing the transaction at $2.34 per share. On May 16 ’24, another insider, Belldegrun Arie, who serves as the Director of the company, bought 1,724,137 shares for $2.90 each. As a result, the insider paid 4,999,997 and bolstered with 1,724,137 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALLO now has a Market Capitalization of 532399200 and an Enterprise Value of 146662112. For the stock, the TTM Price-to-Sale (P/S) ratio is 4095.30 while its Price-to-Book (P/B) ratio in mrq is 0.94. Its current Enterprise Value per Revenue stands at 1685.771 whereas that against EBITDA is -0.542.

Stock Price History:

Over the past 52 weeks, ALLO has reached a high of $6.05, while it has fallen to a 52-week low of $2.18. The 50-Day Moving Average of the stock is -10.55%, while the 200-Day Moving Average is calculated to be -24.59%.

Shares Statistics:

ALLO traded an average of 2.36M shares per day over the past three months and 3524920 shares per day over the past ten days. A total of 208.78M shares are outstanding, with a floating share count of 136.67M. Insiders hold about 34.54% of the company’s shares, while institutions hold 50.59% stake in the company. Shares short for ALLO as of 1715731200 were 36428594 with a Short Ratio of 17.17, compared to 1713139200 on 31360608. Therefore, it implies a Short% of Shares Outstanding of 36428594 and a Short% of Float of 33.029997.

Most Popular